Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer

NEXT STORY
Merus N.V. Announces Proposed Public Offering of Common Shares
PREV STORY
Thingsfactory introduces new technology for fever and behaviour detection in Livestock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis

author_avatar
NASDAQ Market News

Abiomed Surpasses 50,000 Impella® Patients Treated in the United States

author_avatar
NASDAQ Market News

FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer

author_avatar
NASDAQ Market News